Publicaciones científicas
- [DESARROLLO DE TECNOLOGÍAS DE TRANSFERENCIA DE GENES]
- [TERAPIA GÉNICA DE ENFERMEDADES RARAS]
- [ESTRÉS CELULAR E INMUNOTERAPIA EN CÁNCER HEPÁTICO]
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates
Nerea Zabaleta 1, Wenlong Dai 1, Urja Bhatt 1, Cécile Hérate 2, Pauline Maisonnasse 2, Jessica A Chichester 3, Julio Sanmiguel 1, Reynette Estelien 1, Kristofer T Michalson 3, Cheikh Diop 1, Dawid Maciorowski 1, Nathalie Dereuddre-Bosquet 2, Mariangela Cavarelli 2, Anne-Sophie Gallouët 2, Thibaut Naninck 2, Nidhal Kahlaoui 2, Julien Lemaitre 2, Wenbin Qi 4, Elissa Hudspeth 5, Allison Cucalon 1, Cecilia D Dyer 3, M Betina Pampena 6, James J Knox 7, Regina C LaRocque 8, Richelle C Charles 8, Dan Li 1, Maya Kim 1, Abigail Sheridan 1, Nadia Storm 9, Rebecca I Johnson 9, Jared Feldman 10, Blake M Hauser 10, Vanessa Contreras 2, Romain Marlin 2, Raphaël Ho Tsong Fang 2, Catherine Chapon 2, Sylvie van der Werf 11, Eric Zinn 1, Aisling Ryan 1, Dione T Kobayashi 12, Ruchi Chauhan 1, Marion McGlynn 3, Edward T Ryan 13, Aaron G Schmidt 14, Brian Price 15, Anna Honko 9, Anthony Griffiths 9, Sam Yaghmour 4, Robert Hodge 16, Michael R Betts 6, Mason W Freeman 17, James M Wilson 3, Roger Le Grand 18, Luk H Vandenberghe 19
Abstract
The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses and can be deployed easily. Here, AAVCOVID-1, an adeno-associated viral (AAV), spike-gene-based vaccine candidate demonstrates potent immunogenicity in mouse and non-human primates following a single injection and confers complete protection from SARS-CoV-2 challenge in macaques. Peak neutralizing antibody titers are sustained at 1 year and complemented by functional memory T cell responses. The AAVCOVID vector has no relevant pre-existing immunity in humans and does not elicit cross-reactivity to common AAVs used in gene therapy. Vector genome persistence and expression wanes following injection. The single low-dose requirement, high-yield manufacturability, and 1-month stability for storage at room temperature may make this technology well suited to support effective immunization campaigns for emerging pathogens on a global scale.
CITA DEL ARTÍCULO Cell Host Microbe. 2021 Sep 8;29(9):1437-1453.e8. doi: 10.1016/j.chom.2021.08.002. Epub 2021 Aug 7.